Antibody-drug conjugates: an evolving approach for melanoma treatment

ola Kala shared this article with you from Inoreader Antibody-drug conjugates: an evolving approach for melanoma treatment Μέσω Melanoma Research - Current Issue Melanoma continues to be an aggressive and deadly form of skin cancer while therapeutic options are continuously developing in an effort to provide long-term solutions for patients. Immunotherapeutic strategies incorporating antibody-drug conjugates (ADCs) have seen varied levels of success across tumor types and represent a promising approach for melanoma. This review will explore the successes of FDA-approved ADCs to date compared to the ongoing efforts of melanoma-targeting ADCs. The challenges and opportunities for future therapeutic development are also examined to distinguish how ADCs may better impact individuals with malignancies such as melanoma. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.